Neogenix Oncology, Inc. Obtains Patent in Europe Relating to Its NEO-301 Antibody
Neogenix Oncology is pleased to announce that it will be granted a European Patent (“EP”) relating to its NEO-301 antibody (also known as 31.1), to take effect beginning September 23, 2011. The European Patent Office issued a “Decision to Grant” the company’s patent application, designated as EP Patent No. 02726672.5, on December 23, 2010. This patent will be in force until March 15, 2022.